Interaction between gemcitabine and mitomycin-C in vitro

Cancer Chemotherapy and Pharmacology

Volumn 45, Issue 1, 2000, Pages 38-42

  Aung, Tu T ^a   Davis, Mary A ^b   Ensminger, William D ^a   Lawrence, Theodore S ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Colorectal cancer; Gemcitabine (dFdCyd); Mitomycin C (MMC)

Indexed keywords

GEMCITABINE; MITOMYCIN C;

ARTICLE; CALCULATION; CARCINOMA CELL; CLONOGENIC ASSAY; COLON ADENOCARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA ADDUCT; DNA REPAIR; DRUG RESEARCH; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL;

EID: 0033975254     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00006740     Document Type: Article

References (34)

1. 1. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN, et al (1991) A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9: 491
2. 2. Abratt R, Bezwoda W, Falkson G, Goedhals L, Hacking D, Rugg T (1994) Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: A phase II study. J Clin Oncol 12: 1535
3. 3. Baker CH, Banzon J, Bollinger JM, Stubbe J, Samano V, Robins MJ, Lippert B, Jarvi E, Resvick R (1991) 2′-Deoxy-2′-methylenecytidine and 2′-deoxy-2′,2′-difluorocytidine 5′-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase. J Med Chem 34: 1879
4. 4. Braakhuis BJ, Dongen GA van, Vermorken JB, Snow GB (1995) Preclinical in vivo activity of 2′,2′-difluorodeoxycytidine (Gemcitabine) against human head and neck cancer. Cancer Res 51: 221
5. 5. Chou T-C, Talalay P (1984) Quantitative analysis of dose-effective relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Res 22: 27
6. 6. Comis R (1979) Mitomycin C in gastric cancer. In: Carter SK, Crooke ST (eds) Mitomycin C: current status and new developments. Academic Press, New York San Francisco London, p 129
7. 7. Crino L, Scagliotti G, Marangolo M (1997) Cisplatin-gemcitabine in advanced non-small cell lung cancer: a phase II study. J Clin Oncol 15: 297
8. 8. Crooke S, Bradner W (1976) Mytomycin C: a review. Cancer Treat Rev 31: 121
9. 9. Dorr R (1988) New findings in the pharmacokinetic, metabolic, and drug-resistance aspects of mitomycin-C. Semin Oncol 4: 32
10. 10. Fertil B, Dertinger H, Courdi A, Malaise EP (1984) Mean inactivation dose: a useful concept for intercomparison of human cell survival curves. Radiat Res 99: 73
11. 11. Godfrey T (1979) Mitomycin C in breast cancer. In: Carter SK, Crooke ST (eds) Mitomycin C: current status and new developments. Academic Press, New York San Francisco London, p 91
12. 12. Greco WR, Park HS, Rustum YM (1990) Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-beta-D-arabinofuranosylcytosine. Cancer Res 50: 5318
13. 13. Grunwald R, Akrivakis K, Mergenthaler H, Blatter J, Possinger K (1998) Phase I study of gemcitabine and epirubicin for metastatic breast cancer (abstract 241). Proceedings of the 15th Annual Meeting of the American Society of Clinical Oncology
14. 14. Heinemann V, Hertel LW, Grindey GB, Plunkett W (1988) Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res 48: 4024
15. 15. Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, Grindey GB (1990) Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 50: 4417
16. 16. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W (1991) Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51: 6110
17. 17. Kaye SB (1994) Gemcitabine: current status of phase I and II trials (editorial). J Clin Oncol 12: 1527
18. 18. Lawrence TS, Davis MA, Maybaum J, Stetson PL, Ensminger WD (1990) The effect of single versus double-strand substitution on halogenated pyrimidine-induced radiosensitization and DNA strand breakage in human tumor cells. Radiat Res 123: 192
19. 19. Lawrence TS, Chang EY, Hahn TM, Shewach DS (1997) Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2′,2′-difluoro-2′-deoxycytidine (Gemcitabine). Clin Cancer Res 3: 777
20. 20. Matsumoto A, Vos JM, Hanawalt PC (1989) Repair analysis of mitomycin C-induced DNA crosslinking in ribosomal RNA genes in lymphoblastoid cells from Fanconi's anemia patients. Mutat Res 217: 185
21. 21. Moore M, Andersen J, Burris H, Tarassoff P, Green M, Casper E, Portenoy R, Modiano M, Cripps C, Nelson R (1995) A randomized trial of gemcitabine (GEM) versus 5FU as first-line therapy in advanced pancreatic cancer (abstract 473). Proceedings of the 14th Annual Meeting of the American Society of Clinical Oncology
22. 22. Moorsel C van, Veerman G, Bergman A, Guechev A (1997) Combination chemotherapy studies with gemcitabine. Semin Oncol 24 [suppl 7]: 17
23. 23. Peters G, Bergman A, Ruiz van Haperen V, Veerman G, Kuipe RC, Braakhius B (1995) Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 22 [Suppl 11]: 72
24. 24. Rothenberg ML, Moore MJ, Cripps MD, Anderson JS, Portenoy RK, Burris HA, Green MR (1996) A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 14: 347
25. 25. Ruiz van Haperen VWT, Veerman G, Vermorken JB, Peters GJ (1993) 2′,2′-difluorodeoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. Biochem Pharmacol 46: 762
26. 26. Sandler A, Ansari R, McClean J (1995) Gemcitabine plus cisplatin in non-small cell lung cancer: a phase II study. Eur J Cancer 131A: S255
27. 27. Schy WE, Hertel LW, Kroin JS, Bloom LB, Goodman MF, Richardson FC (1993) Effect of a template-located 2′,2′-difluorodeoxycytidine on the kinetics and fidelity of base insertion by Klenow (3′-5′ exonuclease-) fragment. Cancer Res 53: 4582
28. 28. Shewach DS, Lawrence TS (1996) Gemcitabine and radiosensitization in human tumor cells. Invest New Drugs 14: 257
29. 29. Shewach DS, Hahn TM, Chang E, Hertel LW, Lawrence TS (1994) Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res 54: 3218
30. 30. Siegel D, Gibson N, Preush P, Rose D (1990) Metabolism of mitomycin C by DT-diaphorase: role in mitomycin C-induced DNA damage and cytotoxicity in human colon carcinoma cells. Cancer Res 50: 7483
31. 31. Steel GG, Peckham MJ (1979) Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 5: 85
32. 32. Teicher B, Devita V, Hellman S, Rosenberg S, Devita VT, Hellman S, Rosenberg SA (1977) Cancer, principles and practice of oncology, 4th edn. Lippincott, Philadelphia, p 405
33. 33. Tomasz M, Chawala A, Lipman R (1988) Mechanism of monofunctional and bifunctional alkylation of DNA by mitomycin C. Biochemistry 27: 3182
34. 34. Verweij J (1997) Mitomycins. Cancer Chemother Biol Response Modif 16: 48